Carregant...
Treatment-related adverse events and response rate to immune checkpoint inhibition
BACKGROUND: Immune checkpoint inhibition (ICI) represents a novel treatment modality for refractory cancers, and improving prediction of potential responders is critical. METHOD: We hypothesized that ICI is a systemic-effecting mechanism. The objective response rate (ORR) for anti-PD-1, anti-PD-L1,...
Guardat en:
| Publicat a: | J Int Med Res |
|---|---|
| Autors principals: | , , , , |
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
SAGE Publications
2019
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7783260/ https://ncbi.nlm.nih.gov/pubmed/31777292 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/0300060519886454 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|